<DOC>
	<DOCNO>NCT01814865</DOCNO>
	<brief_summary>This study offer patient post-menopausal , breast cancer positive estrogen and/or progesterone hormone receptor test currently await surgery breast cancer . The purpose study determine whether abiraterone acetate different hormonal genomic effect non-steroidal aromatase inhibitor treatment post-menopausal hormonal receptor positive primary operable breast cancer</brief_summary>
	<brief_title>Anti-Proliferative Effects Genomic Alterations Abiraterone Acetate Compared Aromatase Inhibitor Post-menopausal HR+ Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1 . Woman great equal 18 year age postmenopausal determine one following : bilateral surgical oophorectomy age great equal 60 year age &lt; 60 year , amenorrhea great equal 24 month folliclestimulating hormone luteinizing hormone concentration within postmenopausal range 2 . Subjects ER+ ( Allred 38 ) , HER2 primary operable T1T3 breast cancer primary tumor size ≥ 1.5 cm physical examination image study 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status score less equal 1 4 . Criterion modify per amendment 7.1 Clinical laboratory value Screening : hemoglobin great equal 10.0 g/dL neutrophil great equal 1.5 x 109/L platelet great equal100 x 109/L total bilirubin less equal 1.5x upper limit normal ( ULN ) except know diagnosis Gilbert 's syndrome alanine ( ALT ) aspartate ( AST ) aminotransferase less equal 1.5xULN alkaline phosphatase less equal 1.5xULN serum creatinine &lt; 1.5xULN creatinine clearance great equal 45 mL/min serum potassium great equal 3.5 mM serum albumin great equal 3.0 g/dL INR ( PT ) partial thromboplastin time ( PTT ) within normal limit 5 . Systolic blood pressure &lt; 180 mm Hg diastolic blood pressure &lt; 100 mm Hg [ Note : Hypertension control antihypertensive therapy permit ] . 6 . Willing able adhere prohibition restriction specify protocol 7 . Signs inform consent document within 4 week randomization indicate understands purpose procedure require study willing participate study 1 . Prior treatment ketoconazole , aminoglutethimide CYP17 inhibitor . [ Note : Prior treatment ketoconazole ≤7 day permit topical formulation ketoconazole permit ] 2 . Anticancer immunotherapy , investigational agent , anticancer radiotherapy anticancer endocrine therapy within 12 week randomization 3 . Use hormone replacement therapy within past 4 week 4 . Serious uncontrolled nonmalignant disease , include active uncontrolled infection 5 . Clinical biochemical evidence hyperaldosteronism hypopituitarism 6 . Any condition , opinion investigator , would compromise wellbeing patient could prevent , limit , confound protocolspecified assessment 7 . Major thoracic abdominal surgery significant traumatic injury 4 week randomization [ Note : Patients plan surgical procedure conduct local anesthesia exclude study ( e.g . intravascular device insertion ) ] 8 . Gastrointestinal disorder interfere study drug absorption 9 . Positive serology hepatitis B surface antigen hepatitis C antibody 10 . Active symptomatic viral hepatitis chronic liver disease 11 . History clinically significant heart disease , ie , myocardial infarction arterial thrombotic event within 6 month , severe unstable angina , New York Heart Association Class III IV heart disease 12 . Known allergy , hypersensitivity , intolerance abiraterone acetate , prednisone , excipients 13 . Received investigational drug ( include investigational vaccine ) use invasive investigational medical device within 4 week plan first dose study drug currently enrol investigational study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>ER+</keyword>
	<keyword>Stage I-IIIA</keyword>
	<keyword>Operable</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>